Gene-edited porcine liver xenotransplantation: advances and key clinical translation barriers
Abstract
Liver allotransplantation constitutes a vital organ-replacement therapy for end-stage liver disease, yet the global shortage of donor livers severely limits treatment capacity. Porcine liver xenotransplantation, which employs genetically edited pig livers as grafts, holds promise for alleviating donor scarcity and providing bridging organ support for patients with acute liver failure. In recent years, considerable progress has been achieved in preclinical non-human primate (NHP) models and human clinical studies. Benefiting from multi-gene editing, optimized immunosuppressive regimens, and refined surgical techniques, this approach can now effectively avert hyperacute rejection (HAR) and achieve short-term graft functional compensation. Nevertheless, clinical translation of liver xenotransplantation still faces multiple obstacles. Technical bottlenecks include delayed immune injury mediated by non-α-1,3-galactose (α-Gal) antigens, intractable coagulopathy, cross-species incompatibility in metabolism and drug disposition, lack of standardized surgical protocols, and risks of cross-species transmission of porcine viruses. Non-technical challenges encompass inconsistent global regulatory standards, informed-consent issues, animal welfare, and medical equity. Risks posed by exogenous viruses such as porcine cytomegalovirus (PCMV) can be mitigated by establishing designated pathogen-free (DPF) donor pig breeding systems combined with pre-transplant pathogen screening; however, such strategies cannot eliminate porcine endogenous retroviruses (PERV) integrated within the porcine genome, which carry risks of latent reactivation, recombination-mediated mutation, and potential cross-species infection. This review summarizes research progress and core limiting factors in liver xenotransplantation, aiming to provide theoretical references for optimizing donor gene-editing targets, improving immune-coagulation disorder prevention and control, standardizing surgical procedures, and constructing ethical supervision frameworks, so as to facilitate safe and orderly clinical translation of liver xenotransplantation.
Related
- Histotripsy in tumor therapy: advances in non-thermal mechanical ablation, immune modulation, and clinical translation
- Radiomics- based biomarkers for immunotherapy in non-small cell lung cancer: advances, challenges, and future perspectives in biological interpretation and clinical translation
- Mesenchymal Stem Cell-Derived Extracellular Vesicles for Functional Intracellular Delivery: Engineering, Targeting, Cellular Uptake, Biological Barriers, and Therapeutic Translation
- Editorial: The breast cancer tumor microenvironment: from model systems to clinical translation
- Emerging Technologies in Cardiovascular Disease Modeling: Bridging Basic Science and Clinical Translation
BibTeX
@article{gao2026geneedited,
title = {{Gene-edited porcine liver xenotransplantation: advances and key clinical translation barriers}},
author = {Yao Gao and Min He and Hanfei Huang and Zhong Zeng},
journal = {Frontiers in Immunology},
year = {2026},
month = nov,
doi = {10.3389/fimmu.2026.1949083},
url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949083},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Gene-edited porcine liver xenotransplantation: advances and key clinical translation barriers
AU - Yao Gao
AU - Min He
AU - Hanfei Huang
AU - Zhong Zeng
PY - 2026
DA - 2026/11/05
JO - Frontiers in Immunology
DO - 10.3389/fimmu.2026.1949083
UR - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1949083
AB - Liver allotransplantation constitutes a vital organ-replacement therapy for end-stage liver disease, yet the global shortage of donor livers severely limits treatment capacity. Porcine liver xenotransplantation, which employs genetically edited pig livers as grafts, holds promise for alleviating donor scarcity and providing bridging organ support for patients with acute liver failure. In recent years, considerable progress has been achieved in preclinical non-human primate (NHP) models and human clinical studies. Benefiting from multi-gene editing, optimized immunosuppressive regimens, and refined surgical techniques, this approach can now effectively avert hyperacute rejection (HAR) and achieve short-term graft functional compensation. Nevertheless, clinical translation of liver xenotransplantation still faces multiple obstacles. Technical bottlenecks include delayed immune injury mediated by non-α-1,3-galactose (α-Gal) antigens, intractable coagulopathy, cross-species incompatibility in metabolism and drug disposition, lack of standardized surgical protocols, and risks of cross-species transmission of porcine viruses. Non-technical challenges encompass inconsistent global regulatory standards, informed-consent issues, animal welfare, and medical equity. Risks posed by exogenous viruses such as porcine cytomegalovirus (PCMV) can be mitigated by establishing designated pathogen-free (DPF) donor pig breeding systems combined with pre-transplant pathogen screening; however, such strategies cannot eliminate porcine endogenous retroviruses (PERV) integrated within the porcine genome, which carry risks of latent reactivation, recombination-mediated mutation, and potential cross-species infection. This review summarizes research progress and core limiting factors in liver xenotransplantation, aiming to provide theoretical references for optimizing donor gene-editing targets, improving immune-coagulation disorder prevention and control, standardizing surgical procedures, and constructing ethical supervision frameworks, so as to facilitate safe and orderly clinical translation of liver xenotransplantation.
SN - 1664-3224
ER -